You just read:

Clovis Oncology, Inc. Receives License for Worldwide Development and Commercialization Rights to Pfizer's Oral and IV PARP Inhibitor PF-01367338

News provided by

Clovis Oncology, Inc.

02 Jun, 2011, 20:45 BST